newsfilter
← Latest News
PR Newswire·

BrainStorm Cell Therapeutics Announces Pricing of $4.0 Million Registered Direct Offering

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) (the "Company"), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, ...